Core--Human tissue (DNA genotyping and sequencing)

核心--人体组织（DNA基因分型和测序）

• 批准号: 6695795
• 负责人: DIANNA M MILEWICZ
• 金额: $ 14.34万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6695795
• 关键词: DNA; biomedical facility; clinical trials; functional /structural genomics; genetic registry /resource /referral center; genotype; high throughput technology; human tissue; nucleic acid sequence; proteomics; stroke; stroke therapy

DESCRIPTION (provided by the applicant): Recent events and dramatic progress in genetics research conspire to create the need for this Core Laboratory as part of an acute stroke therapy Program Project. Genetic profiling of stroke patients may help better identify and predict clinical behavior. For instance, genetic markers might predict tendency to hemorrhage after rtPA, and response to various neuroprotective therapies, particularly those based on targeting gene-activated pathways. Through proteomics, we may be able to develop a diagnostic profile that can help determine the presence, amount, and age of ischemic damage, thereby providing assurance to Clinicians when deciding if a patient indeed has had a stroke that might qualify for urgent treatment. The potential for these Clinical applications led the recent Stroke PRG to identify the study of genomics and proteomics as a top research priority. The PRG group called for banking of blood samples for future genetic studies to be obtained as part of all clinical trials, along with careful documentation of clinical and demographic features on each patient. The Genetics program at the University of Texas Houston Medical School, under the direction of Drs. Dianna Milewicz and Eric Boerwinkle, has undergone exponential growth in its research activities, and is anxious to establish collaborative research ties with vigorous Clinical research groups like our Stroke program. While no specific research protocols are proposed in this Program Project, the establishment of this Core Laboratory under the direction of Dr. Milewicz will position us to begin novel genetic studies within the context of our clinical trials. Furthermore, it will enable us to participate in collaborative genetic research among other SPOTRIAS centers. SPECIFIC AIM: To support genomics-based clinical research on acute stroke patients in the CRC. As recommended by the Stroke PRG, the laboratory will harvest and bank genomic DNA samples from all patients enrolled in the acute stroke trials carried out as part of the Program Project, and provide high-throughput DNA genotyping and sequencing. The facility will support ongoing collaborative research projects within the institution and will serve as a resource for collaborative studies across all the SPOTRIAS centers.

描述（由申请人提供）：作为急性中风治疗计划项目的一部分，遗传学研究中的最新事件和巨大的进展共同创造了对该核心实验室的需求。中风患者的基因分析可能有助于更好地识别和预测临床行为。例如，遗传标记可能会预测RTPA后出血的趋势，以及对各种神经保护疗法的反应，尤其是基于靶向基因激活途径的趋势。通过蛋白质组学，我们可能能够开发出可以帮助确定缺血性损害的存在，数量和年龄的诊断特征，从而在确定患者是否确实有可能有资格接受紧急治疗的情况下为临床医生提供保证。 这些临床应用的潜力导致最近的中风PRG确定基因组学和蛋白质组学的研究是最重要的研究优先事项。 PRG小组呼吁将血液样本作为所有临床试验的一部分获得未来的遗传研究，并仔细记录每个患者的临床和人口特征。 德克萨斯大学休斯顿大学医学院的遗传学计划，在博士的指导下。戴安娜·米勒维兹（Dianna Milewicz）和埃里克·博世（Eric Boerwinkle）在其研究活动中经历了指数级的增长，并且渴望与诸如中风计划等有力的临床研究小组建立合作研究联系。尽管该计划项目没有提出具体的研究方案，但在Milewicz博士的指导下，建立该核心实验室将使我们在我们的临床试验的背景下开始新的遗传研究。此外，它将使我们能够参与其他现场中心的合作遗传研究。 具体目的：支持基于基因组学的CRC急性中风患者的临床研究。按照中风PRG的建议，实验室将从所有参加急性中风试验的患者中收集和库存基因组DNA样品作为计划项目的一部分，并提供高通量DNA基因分型和测序。该设施将支持该机构内部正在进行的合作研究项目，并将作为所有现货中心的合作研究的资源。